EXAS Abuzz, MACK Makes Deal With Ipsen, XENE Awaits Data

Exact Sciences Corp. (EXAS) expects to report revenues between $34.9 million and $35.4 million for the fourth quarter ended Dec. 31, 2016, which represents an increase of 142 percent from the same quarter of 2015.

from RTT - Biotech http://ift.tt/2jj7lZr
via IFTTT